T + T – Normal size
Al Qassimi Hospital in Sharjah, part of the Emirates Health Services Corporation, announced today a pioneering medical achievement in the treatment of chronic ischemia threatening the limbs below the knee after successfully implanting the first everolimus-loaded, self-dissolving Esprit™ BTK stent in the Europe, Middle East and Africa region.
The new Esprit stent, developed by Abbott Medical, is the first of its kind and the latest solution for treating blood vessels in patients with chronic ischemia that threatens the limbs below the knee.
This innovative stent made of suture-like materials has recently received FDA approval, offering a new treatment option that reduces the risk of long-term complications.
Before dissolving, the stent keeps the blood vessel open until the drug is released, which helps it heal and strengthen it enough to stay open on its own.
Dr. Arif Al Nouriani, Director of Al Qassimi Hospital in Sharjah, stressed that the success of the hospital’s medical team in implanting the modern and innovative “Esprit” stent represents a unique achievement and a milestone in the development of the health sector in the country, as this stent provides an innovative therapeutic solution that will contribute to improving the quality of life of patients by treating problems of hardened arteries below the knee, which often lead to amputation and high rates of death after five years of treatment.
He pointed out that the achievement reflects the Emirates Health Services Corporation’s continuous commitment to improving the quality of healthcare and making a qualitative shift in people’s lives by adopting an innovative approach based on advanced medical technology, in line with the vision of the wise leadership and the objectives of the “We the Emirates” Vision 2031 and the UAE Centennial 2071, which focus on promoting innovation in all vital sectors, including the health sector.
